BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-16 out of 16 found
  Current Search:  femara: 16     

HTML
100%
Everolimus Shows Potential to Enhance Breast Cancer Therapies
Findings from a Phase II study show that everolimus (RAD001) enhances tumor shrinkage when given in combination with letrozole tablets (Femara) to postmenopausal women with newly diagnosed estrogen receptor-positive (ER+) breast cancer...
CancerWatch:  Jul 25 2008 6:50AM
Matching: femara
Find similar documents
HTML
100%
Strong quarterly performance for Novartis
LONDON (MarketWatch) -- Novartis on Thursday reported that second-quarter net income increased a stronger-than-expected 21%, helped by growing sales of cancer and cardiovascular drugs.

Novartis also affirmed that it expects record sales...

MarketWatch:  Jul 18 2008 4:20PM
Matching: femara
Find similar documents
HTML
100%
Novartis net profit up by 13% to US$4.6 billion
Novartis has posted satisfactory performance during the first half ended June 2008.

Its net profit went up by 13 per cent to US$4,574 million from $4,035 million in the corresponding period of last year.

Its net sales increased by 11 per...

PharmaBiz:  Jul 18 2008 11:56AM
Matching: femara
Find similar documents
HTML
100%
Novartis Q2 profit up 12%; backs FY08 forecast - update 2
Swiss healthcare company Novartis AG (NVS: News, Chart, Quote ) reported a 12% rise in its second-quarter profit, driven by strong segmental sales, mainly in Pharmaceuticals and generics subsidiary Sandoz.

The company also affirmed its...

RTTNews.com:  Jul 17 2008 10:11AM
Matching: femara
Find similar documents
HTML
100%
Novartis Q2 profit up 12%; backs FY08 forecast
Swiss healthcare company Novartis AG (NVS: News, Chart, Quote ) reported a 12% rise in its second-quarter profit, driven by strong segmental sales, mainly in Pharmaceuticals and generics subsidiary Sandoz.

The company also affirmed its...

RTTNews.com:  Jul 17 2008 9:57AM
Matching: femara
Find similar documents
HTML
100%
Novartis Q2 profit up 12%; backs FY08 forecast - update 2
Swiss healthcare company Novartis AG (NVS | Quote | Chart | News | PowerRating) reported a 12% rise in its second-quarter profit, driven by strong segmental sales, mainly in Pharmaceuticals and generics subsidiary Sandoz.

The company also...

TradingMarkets:  Jul 17 2008 9:55AM
Matching: femara
Find similar documents
HTML
100%
PRESS RELEASE Novartis Gains Momentum With -2- (DJ)
healthcare.

Net sales from continuing operations for the Group are expected to rise at a mid-single-digit rate, and at a low-single-digit growth rate in the Pharmaceuticals Division, both in local currencies.

Sandoz is now expected to...

Easy Bourse:  Jul 17 2008 7:05AM
Matching: femara
Find similar documents
HTML
100%
Financial Report: Novartis 2Q
2Q Earnings: $2.3 billion (+17%) YTD Revenues: $20.6 billion (+11%) YTD Earnings: $4.6 billion (+13%) Comments: Pharmaceutical sales were $6.9 billion (+14%) in the quarter and $13.2 billion (+10%) in 1H08, driven by Diovan sales along with...
Contract Pharma:  Jul 17 2008 3:24PM
Matching: femara
Find similar documents
HTML
100%
Novartis shows strong Q2 growth
Novartis has surpassed estimates for its second quarter performance, boosted by higher than expected sales of its flagship cardiovascular and oncology brands.

Strong sales of Glivec and Femara in oncology and Diovan in its...

Pharmafocus:  Jul 17 2008 2:10PM
Matching: femara
Find similar documents
HTML
100%
Novartis shows strong Q2 growth
Novartis has surpassed estimates for its second quarter performance, boosted by higher than expected sales of its flagship cardiovascular and oncology brands.

Strong sales of Glivec and Femara in oncology and Diovan in its...

Pharmafocus:  Jul 17 2008 12:51PM
Matching: femara
Find similar documents
HTML
100%
PRESS RELEASE Novartis Gains Momentum With -4- (DJ)
therapy for patients with cancer that has spread to the bones, was unchanged as fast expansion in some markets offset the US and Europe.

Growth for this class of medicines began to slow in 2007 with patients receiving treatment less...

Easy Bourse:  Jul 17 2008 7:05AM
Matching: femara
Find similar documents
HTML
100%
42nd International Childrens Games @ Kezar Stadium
Topic - Topic - Loan Online Cigarettes Medical tests Top casino Free Ringtones Medicine news Building materials Cases Intimate goods Bracelets Cheap drugs online shop Ear rings Suits Cars Rolex Replica Cheap pharmacy shop ables Autos...
Haight-Ashbury Beat:  Jul 10 2008 9:31PM
Matching: femara
Find similar documents
HTML
100%
New inhibitors of breast cancer cells identified
What breastcancer.org says about this article Most breast cancers are hormone receptor-positive.

The hormone estrogen binds to hormone receptors and in so doing can promote the growth of hormone-receptor-positive breast cancers.

Hormonal...

Breastcancer.org:  Jun 21 2008 12:45AM
Matching: femara
Find similar documents
HTML
100%
Letrozole Slows Breast Cancer Long After End of Ta
A new study has confirmed that adjuvant therapy with letrozole (Femara, Novartis Pharmaceuticals) can be a powerful weapon for preventing breast cancer recurrence in postmenopausal women with hormone receptorpositive diseaseeven when...
Pharmacy Practice News:  Jun 19 2008 4:19AM
Matching: femara
Find similar documents
HTML
100%
Study shows everolimus may offer novel treatment strategy for breast cancer
Early proof-of-concept studies presented at ASCO show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments.
PharmaBiz:  Jun 3 2008 10:01AM
Matching: femara
Find similar documents
HTML
100%
Novartis says new data shows RAD001 breast cancer potential
ZURICH (Thomson Financial) - Novartis AG said new study data shows that RAD001 may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments....
Sharewatch:  Jun 2 2008 6:07AM
Matching: femara
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.